Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103

Discovery and saturation analysis of cancer genes across 21 tumour types

Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Hauschild, A., Grob, J., Демидов, Л. В., Jouary, T., Gutzmer, R., Millward, M. J., Rutkowski, P. L., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 3,050

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,875

Integrated genomic characterization of pancreatic ductal adenocarcinoma

Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

Bryant, K. L., Stalnecker, C. A., Zeitouni, D., Klomp, J. E., Peng, S., Tikunov, A. P., Gunda, V., Pierobon, M., Waters, A. M., George, S. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0368-8 · Cited by 692

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., et al. (2017) · Nature · doi:10.1038/nature23291 · Cited by 562

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M., & Watson, I. R. (2018) · Oncogene · doi:10.1038/s41388-018-0171-x · Cited by 562

Targeting Alterations in the RAF–MEK Pathway

Yaeger, R. D., & Corcoran, R. B. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1321 · Cited by 491

New perspectives for targeting RAF kinase in human cancer

Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404

Drugging RAS: know the enemy

Papke, B., & Der, C. J. (2017) · Science · doi:10.1126/science.aam7622 · Cited by 399

From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer

Nevala-Plagemann, C., Hidalgo, M. M., & Garrido‐Laguna, I. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0281-6 · Cited by 403

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

Aguirre, A. J., Nowak, J. A., Camarda, N. D., Moffitt, R. A., Ghazani, A. A., Hazar-Rethinam, M., Raghavan, S., Kim, J., Brais, L. K., Ragon, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0275 · Cited by 367

Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers

Singhi, A. D., George, B., Greenbowe, J. R., Chung, J., Suh, J., Maitra, A., Klempner, S. J., Hendifar, A., Milind, J. M., Golan, T., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.037 · Cited by 348

Translational advances in pancreatic ductal adenocarcinoma therapy

Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 255

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling

Karoulia, Z., Wu, Y., Ahmed, T. A., Xin, Q., Bollard, J., Krepler, C., Wu, X., Zhang, C., Bollag, G. E., Herlyn, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.024 · Cited by 205

Targeting oncogenic Raf protein-serine/threonine kinases in human cancers

Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 199

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism

Vaseva, A. V., Blake, D. R., Gilbert, T. S. K., Ng, S., Hostetter, G. H., Azam, S. H., Ozkan‐Dagliyan, I., Gautam, P., Bryant, K. L., Pearce, K. H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.001 · Cited by 187

Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures

Singhi, A. D., Nikiforova, M. N., Chennat, J. S., Papachristou, G. I., Khalid, A., Rabinovitz, M., Das, R. K., Sarkaria, S., Ayasso, M. S., Wald, A. I., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317817 · Cited by 177

Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis

Chakraborty, R., Burke, T. M., Hampton, O. A., Zinn, D. J., Lim, K. P. H., Abhyankar, H. A., Scull, B., Kumar, V., Kakkar, N., Wheeler, D. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733790 · Cited by 170

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors

Schreck, K. C., Grossman, S. A., & Pratilas, C. A. (2019) · Cancers · doi:10.3390/cancers11091262 · Cited by 150

Molecular Pathways and Mechanisms of BRAF in Cancer Therapy

Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

Xiang, Y., Liu, X., Wang, Y., Zheng, D., Meng, Q., Jiang, L., Yang, S., Zhang, S., Zhang, X., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366260 · Cited by 152

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136

Targeting the Raf kinases in human cancer: the Raf dimer dilemma

Durrant, D., & Morrison, D. K. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.399 · Cited by 138

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives

Crispo, F., Notarangelo, T., Pietrafesa, M., Lettini, G., Storto, G., Sgambato, A., Maddalena, F., & Landriscina, M. (2019) · Cancers · doi:10.3390/cancers11091388 · Cited by 111

Current Insights of BRAF Inhibitors in Cancer

Agianian, B., & Gavathiotis, E. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01306 · Cited by 103

Molecular targeted therapy of BRAF -mutant colorectal cancer

Ducreux, M. P., Chamseddine, A. N., Laurent‐Puig, P., Smolenschi, C., Hollebecque, A., Dartigues, P., Samalin, E., Boige, V., Malka, D., & Gelli, M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919856494 · Cited by 105

Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes

Lee, L. H., Gasilina, A., Roychoudhury, J., Clark, J. P., McCormack, F. X., Pressey, J. G., Grimley, M. S., Lorsbach, R. B., Ali, S. M., Bailey, M., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.89473 · Cited by 98

A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

Sullivan, R. J., Hollebecque, A., Flaherty, K. T., Shapiro, G. I., Rodon, J. A., Millward, M., Zhang, W., Gao, L., Sykes, A. K., Willard, M. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0681 · Cited by 88

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

Vo, J. N., Wu, Y., Mishler, J., Hall, S., Mannan, R., Wang, L., Yu, N., Zhou, J. R., Hopkins, A. C., Estill, J. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31430-0 · Cited by 103

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution

Anderson, G. R., Winter, P. S., Lin, K. H., Nussbaum, D. P., Cakir, M., Stein, E. M., Soderquist, R. S., Crawford, L., Leeds, J. C., Newcomb, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.006 · Cited by 80

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution

Nunno, V. D., Gatto, L., Tosoni, A., Bartolini, S., & Franceschi, E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1067252 · Cited by 79

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective

Yan, N., Guo, S., Zhang, H., Zhang, Z., Shen, S., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.863043 · Cited by 80

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1

Chen, S.-H., Gong, X., Zhang, Y., Horn, R. D. V., Yin, T., Huber, L., Burke, T., Manro, J. R., Iversen, P. W., Wu, W., et al. (2017) · Oncogene · doi:10.1038/onc.2017.384 · Cited by 74

RAF kinase dimerization: implications for drug discovery and clinical outcomes

Brummer, T., & McInnes, C. (2020) · Oncogene · doi:10.1038/s41388-020-1263-y · Cited by 72

CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles

Jain, P., Fierst, T. M., Han, H. J., Smith, T. L., Vakil, A., Storm, P. B., Resnick, A. C., & Waanders, A. J. (2017) · Oncogene · doi:10.1038/onc.2017.276 · Cited by 72

A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF V600E-Mutant Brain Tumor

Wang, J., Yao, Z., Jonsson, P., Allen, A. N., Qin, A. C. R., Uddin, S., Dunkel, I. J., Petriccione, M., Manova, K., Haque, S. S., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1263 · Cited by 69

Signaling from RAS to RAF: The Molecules and Their Mechanisms

Jeon, H., Tkacik, E., & Eck, M. J. (2024) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052521-040754 · Cited by 64

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf −/− mouse model

Chapeau, E. A., Gembarska, A., Durand, E. Y., Mandon, E., Estadieu, C., Romanet, V., Wiesmann, M., Tiedt, R., Lehar, J., de Weck, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620262114 · Cited by 64

Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis

Cao, X., Duan, M., Zhao, A., Cai, H., Chen, J., Gao, X., Liu, T., Cai, H., Zhang, L., Sun, J. H., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26412 · Cited by 60

Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis

Yuan, J., Ng, W. H., Tian, Z., Yap, J., Baccarini, M., Chen, Z., & Hu, J. (2018) · Science Signaling · doi:10.1126/scisignal.aar6795 · Cited by 63

Targeted therapy and drug resistance in thyroid cancer

Zhang, Y., Xing, Z., Liu, T., Tang, M., Mi, L., Zhu, J., Wu, W., & Wei, T. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114500 · Cited by 55

The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants

Yuan, J., Ng, W. H., Lam, P. Y. P., Wang, Y., Xia, H., Yap, J., Guan, S. P., Lee, A. S. G., Wang, M., Baccarini, M., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0365-2 · Cited by 57

BRAF mutation leading to central nervous system rosai‐dorfman disease

Richardson, T. E., Wachsmann, M., Oliver, D., Abedin, Z. R., Ye, D., Burns, D. K., Raisanen, J. M., Greenberg, B. M., & Hatanpaa, K. J. (2018) · Annals of Neurology · doi:10.1002/ana.25281 · Cited by 54

The mechanism of Raf activation through dimerization

Zhang, M., Maloney, R., Jang, H., & Nussinov, R. (2021) · Chemical Science · doi:10.1039/d1sc03444h · Cited by 52

Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study

Kemps, P. G., Zondag, T. C. E., Arnardóttir, H. B., Solleveld‐Westerink, N., Borst, J., Steenwijk, E. C., van Egmond, D., Swennenhuis, J. F., Stelloo, E., Trambusti, I., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007947 · Cited by 52

Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?

Rusinek, D., Chmielik, E., Krajewska, J., Jarząb, M., Oczko‐Wojciechowska, M., Czarniecka, A., & Jarząb, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081817 · Cited by 48

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer

Singh, H., Keller, R. B., Kapner, K. S., Dilly, J., Raghavan, S., Yuan, C., Cohen, E. F., Tolstorukov, M. Y., Andrews, E., Brais, L. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3930 · Cited by 53

KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer

Kang, Y. W., Lee, J. E., Jung, K. H., Son, M. K., Shin, S., Kim, S., Fang, Z., YAN, H. H., Park, J. H., Han, B., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.013 · Cited by 45

Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer

Kattan, W. E., Liu, J., Montufar‐Solis, D., Hong, L., Barathi, B. B., van der Hoeven, R., Zhou, Y., & Hancock, J. F. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114126118 · Cited by 45

Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022

Singh, A. K., Sonawane, P., Kumar, A., Singh, H., Naumovich, V., Pathak, P., Grishina, M., Khalilullah, H., Jaremko, M., Emwas, A.-H. M., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c00332 · Cited by 47

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations

Yao, Y.-M., Donoho, G. P., Iversen, P. W., Zhang, Y., Horn, R. D. V., Forest, A., Novosiadly, R. D., Webster, Y., Ebert, P. J., Bray, S. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3250 · Cited by 45

BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations

Sheikine, Y., Pavlick, D. C., Klempner, S. J., Trabucco, S. E., Chung, J., Rosenzweig, M. R., Wang, K., Velcheti, V., Frampton, G. M., Peled, N., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00172 · Cited by 46

Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives

Adamopoulos, C., Cave, D. D., & Papavassiliou, A. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031631 · Cited by 43

Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer

Koujima, T., Tazawa, H., Ieda, T., Araki, H., Fushimi, T., Shoji, R., Kuroda, S., Kikuchi, S., Yoshida, R., Umeda, Y., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.03.016 · Cited by 48

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma

Schreck, K. C., Morin, A., Zhao, G., Allen, A. N., Flannery, P., Glantz, M., Green, A. L., Jones, C., Jones, K. L., Kilburn, L. B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2660 · Cited by 42

Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption

Thomas, R. J., Wiley, C. A., Droste, E. L., Robertson, J. B., Inman, B. A., & Breen, M. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010575 · Cited by 40

Targeting CRAF kinase in anti-cancer therapy: progress and opportunities

Wang, P., Laster, K. V., Jia, X., Dong, Z., & Liu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01903-x · Cited by 43

RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development

Bai, Y., Qiao, Y., Li, M., Yang, W., Chen, H., Wu, Y., & Zhang, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116123 · Cited by 42

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies

Riaud, M., Maxwell, J., Soria‐Bretones, I., Dankner, M., Li, M., & Rose, A. A. N. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00650-x · Cited by 40

Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling

Cope, N. J., Novak, B., Liu, Z., Cavallo, M., Gunderwala, A. Y., Connolly, M., & Wang, Z. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011536 · Cited by 38

Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains

Weinberg, F., Griffin, R., Fröhlich, M., Heining, C., Braun, S. L., Spohr, C., Iconomou, M., Hollek, V., Röring, M., Horak, P., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1021-1 · Cited by 39

Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency

Khaliq, M., & Fallahi‐Sichani, M. (2019) · Cancers · doi:10.3390/cancers11101480 · Cited by 39

Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment

Tanaka, H. Y., Nakazawa, T., Enomoto, A., Masamune, A., & Kano, M. R. (2023) · Cancers · doi:10.3390/cancers15030724 · Cited by 42

BRAF internal deletions and resistance to BRAF / MEK inhibitor therapy

Johnson, D. B., Childress, M. A., Chalmers, Z. R., Frampton, G. M., Ali, S. M., Rubinstein, S. M., Fabrizio, D. A., Ross, J. S., Balasubramanian, S., Miller, V. A., et al. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12674 · Cited by 37

Drug resistance in targeted cancer therapies with RAF inhibitors

Degirmenci, U., Yap, J., Sim, Y. R. M., Qin, S., & Hu, J. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.36 · Cited by 36

Coordinating ERK signaling via the molecular scaffold Kinase Suppressor of Ras

Frodyma, D. E., Neilsen, B. K., Costanzo-Garvey, D. L., Fisher, K. W., & Lewis, R. E. (2017) · F1000Research · doi:10.12688/f1000research.11895.1 · Cited by 37

Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers

Pham, N., Radulovich, N., Ibrahimov, E., Martins-Filho, S. N., Li, Q., Pintilie, M., Weiss, J., Raghavan, V., Cabanero, M., Denroche, R. E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90049-1 · Cited by 33

The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF–MEK1/2–ERK1/2 Pathway

Bilal, F., Arenas, E. J., Pedersen, K., Martínez-Sabadell, A., Nabet, B., Guruceaga, E., Vicent, S., Tabernero, J. M., Macarulla, T. M., & Arribas, J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4263 · Cited by 32

RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics

Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 33

Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis

Ipsaro, J. J., Shen, C., Arai, E., Xu, Y., Kinney, J. B., Joshua‐Tor, L., Vakoc, C. R., & Shi, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172177 · Cited by 31

Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment

Vilachã, J. F., Mitchel, S. C., Akele, M. Z., Evans, S., & Groves, M. R. (2020) · Crystals · doi:10.3390/cryst10090725 · Cited by 29

Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution

Monberg, M. E., Geiger, H., Lee, J. J., Sharma, R., Semaan, A., Bernard, V., Wong, J., Wang, F., Liang, S., Swartzlander, D. B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31376-3 · Cited by 30

Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies

Hendifar, A. E., Blais, E. M., Wolpin, B. M., Subbiah, V., Collisson, E. A., Singh, I., Cannon, T. L., Shaw, K. R. M., Petricoin, E. F., Klempner, S. J., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00494 · Cited by 31

Mechanism and inhibition of BRAF kinase

Gunderwala, A. Y., Cope, N. J., & Wang, Z. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102205 · Cited by 31

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF -Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Yaeger, R. D., McKean, M. A., Haq, R., Beck, J. T., Taylor, M. H., Cohen, J. E., Bowles, D. W., Gadgeel, S. M., Mihalcioiu, C. L. D., Papadopoulos, K. P., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0024 · Cited by 30

Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities

Lee, M. S., & Pant, S. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321255 · Cited by 30

Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer

Pan, J., Zhou, H. K., Zhu, S.-B., Huang, J.-L., Zhao, X.-X., Ding, H., & Pan, Y.-L. (2018) · Cancer Management and Research · doi:10.2147/cmar.s170105 · Cited by 28

Paclitaxel anticancer activity is enhanced by the MEK 1/2 inhibitor PD98059 in vitro and by PD98059-loaded nanoparticles in BRAFV600E melanoma-bearing mice

Mekkawy, A. I., Naguib, Y. W., Alhaj-Suliman, S. O., Wafa, E. I., Ebeid, K., Acri, T. M., & Salem, A. K. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120876 · Cited by 27

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Weng, W., Meng, T., Pu, J., Ma, L., Shen, Y., Wang, Z., Pan, R., Wang, M., Chen, C., Wang, L., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0198 · Cited by 28

Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R

Wajapeyee, N., Parajuli, K. R., Chava, S., Pattanayak, R., Manna, D. L. D., Shrestha, D., Yang, E. S.-H., Cai, G., Johnson, D. B., & Gupta, R. (2020) · Oncogenesis · doi:10.1038/s41389-020-0228-x · Cited by 28

New Targets in Non–Small Cell Lung Cancer

Park, S. J., More, S., Murtuza, A., Woodward, B. D., & Husain, H. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.010 · Cited by 26

BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities

Ciner, A., Jiang, Y., & Hausner, P. F. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0626 · Cited by 25

Current Insights into the Role of BRAF Inhibitors in Treatment of Melanoma

Kumar, P., Singh, A. K., Kumar, A., & Thareja, S. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220624164152 · Cited by 24

Disrupted molecular glue complex drives RAS inhibitor resistance

Sang, B., Ye, L. F., Fu, Z., Pourfarjam, Y., Cuevas-Navarro, A., Fan, S., Hu, F., Washington, A., Rodriguez, D. J., Vides, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.031 · Cited by 43

Genomic profile of columnar cell variant of papillary thyroid carcinoma

Janovitz, T., Williamson, D. F. K., Wong, K. S., Dong, F., & Barletta, J. A. (2021) · Histopathology · doi:10.1111/his.14374 · Cited by 23

Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.

Desai, A., Menon, S. P., & Dy, G. K. (2016) · PubMed Central · doi:10.28092/j.issn.2095-3941.2016.0008 · Cited by 22

The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of αC-β4 loop

Yap, J., Deepak, R. N. V. K., Tian, Z., Ng, W. H., Goh, K. C., Foo, A., Tee, Z. H., Mohanam, M. P., Sim, Y. R. M., Degirmenci, U., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg0390 · Cited by 21

Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis

Gao, X., Li, J., & Cao, X. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00917-0 · Cited by 22

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2

Chen, W., & Park, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914837 · Cited by 21

A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies

Li, J., Liu, W., Mojumdar, K., Kim, H., Zhou, Z., Ju, Z., Kumar, S. V., Ng, P. K., Chen, H., Davies, M. A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00817-x · Cited by 23

Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases

Gampa, G., Kim, M., Mohammad, A. S., Parrish, K. E., Mladek, A. C., Sarkaria, J. N., & Elmquist, W. F. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.253708 · Cited by 20

Anti‐angiogenic effects of the blue‐green alga Arthrospira platensis on pancreatic cancer

Markova, I., Koníčková, R., Vaňková, K., Leníček, M., Kolář, M., Strnad, H., Hradilová, M., Šáchová, J., Rasl, J., Klímová, Z., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14922 · Cited by 19

Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation

Khoury, J. D., Tashakori, M., Yang, H. Y., Loghavi, S., Wang, Y., Wang, J., Piya, S., & Borthakur, G. M. (2020) · Cancers · doi:10.3390/cancers12123511 · Cited by 19

Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer

Diehl, J. N., Hibshman, P. S., Ozkan‐Dagliyan, I., Goodwin, C. M., Howard, S. V., Cox, A. D., & Der, C. J. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.008 · Cited by 18

Targeting RAF dimers in RAS mutant tumors: From biology to clinic

Yin, H., Tang, Q., Xia, H., & Bi, F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.018 · Cited by 18

Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance

Wang, L., Zhu, G., Zhang, Q., Duan, C., Zhang, Y., Zhang, Z., Zhou, Y., Lu, T., & Tang, W. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob00518k · Cited by 18

The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer

Zhang, L., Zheng, L., Yang, Q., & Sun, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.882940 · Cited by 19

Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase

Rohrer, L., Spohr, C., Beha, C., Griffin, R., Braun, S. L., Halbach, S., & Brummer, T. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01146-9 · Cited by 17

BRAF Δβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability

Lauinger, M., Christen, D., Klar, R. F. U., Roubaty, C., Heilig, C. E., Stumpe, M., Knox, J. J., Radulovich, N., Tamblyn, L., Xie, I. Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade7486 · Cited by 17

RAF and MEK Inhibitors in Non-Small Cell Lung Cancer

Adamopoulos, C., Papavassiliou, K. A., Poulikakos, P. I., & Papavassiliou, A. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094633 · Cited by 18

BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma

Pratt, D. W., Camelo-Piragua, S. I., McFadden, K. A., Leung, D., Mody, R. J., Chinnaiyan, A. M., Koschmann, C. J., & Venneti, S. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0525-1 · Cited by 17

Abstract 2142: Novel oncogenic BRaf deletions functioning as BRaf homodimer and sensitive to inhibition by LY3009120, a pan Raf and Raf dimer inhibitor

Chen, S.-H., Buchanan, S. G., Zhang, Y., Horn, R. D. V., Yin, T., Yadav, V., Wong, S. S., Huber, L., Henry, J. R., Conti, I., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-2142

BRAF Δβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability

Lauinger, M., Christen, D., Klar, R. F. U., Roubaty, C., Heilig, C. E., Stumpe, M., Knox, J. J., Radulovich, N., Tamblyn, L., Xie, I. Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade7486 · Cited by 17

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Peng, S.-B., Henry, J. R., Kaufman, M. D., Lu, W.-P., Smith, B. D., Vogeti, S., Rutkoski, T. J., Wise, S., Chun, L., Zhang, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.002 · Cited by 303

Abstract DDT02-02: Identification of LY3009120 as a pan inhibitor of Raf isoforms and dimers with minimal paradoxical activation and activities against BRaf or Ras mutant tumor cells

Peng, S.-B., Henry, J. R., Kaufman, M. D., Lu, W.-P., Smith, B. D., Vogeti, S., Wise, S., Zhang, Y., Horn, R. D. V., Zhang, X., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-ddt02-02 · Cited by 2

Abstract 4374: Activation mechanism of oncogenic C-helix shifting mutations in BRAF, EGFR, and HER2

Foster, S. A., Whalen, D. M., Özen, A., Wongchenko, M. J., Yin, J., Yen, I., Schaefer, G., Mayfield, J. D., Chmielecki, J., Stephens, P. J., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4374